![]() ![]() CODX created their coronavirus test in only one week.From doing further research, we believe the following are strong signs that suggest this test is ineffective. New Strong Signs That Co-Diagnostics' Coronavirus Test Is IneffectiveĬODX's coronavirus test kit is called the Logix Smart Coronavirus 2019 (COVID-19) Test Kit, described on the CODX website here. We have found more evidence that its device is likely not effective and we reiterate our $1 price target. Now that the stock price has appreciated significantly, we decided to give CODX another look. Note that those investors who shorted CODX and held their position when we published our first report may have taken heavy losses and may have gotten stopped out. On 2/18/20, we published a bearish article on Co-Diagnostics ( NASDAQ: CODX) titled: Co-Diagnostics Coronavirus Test Is Likely Ineffective - $1 Price Target. Warrant Agreement between Co-Diagnostics, Inc and VStock Transfer, LLC.Editor's note: This article was updated on 3/17 in response to reader inquiries. Reports Second Quarter 2022 Financial Results Second quarter results impacted by volume declines Further progress on the development of the Co-Dx PCR Home platformĪmendment to Agreement and Plan of Merger by and among Co-Diagnostics, Inc., Advanced Conceptions, Inc., and Richard Abbott, as Company RepresentativeĪmendment to Agreement and Plan of Merger by and among Co-Diagnostics, Inc., Idaho Molecular, Inc., and Kirk Ririe, as Company RepresentativeĬo-Diagnostics Reports Solid First Quarter 2022 Financial Results Strong results highlighted by record first quarter revenue of $22.7 million and diluted EPS of $0.34Īmended and Restated Bylaws of Co-Diagnostics, Inc.Ĭo-Diagnostics Reports Full Year 2021 Financial Results Achieved Record Full Year Revenue of $97.9 Million Strength in Sales Momentum Provides Foundation to Achieve Solid FY’22 Reports Third Quarter 2022 Financial Results Nearing commencement of clinical evaluations for the Co-Dx PCR Home platform COVID-19 test volumes continue to impact third quarter resultsĬo-Diagnostics, Inc. Reports Full Year 2022 Financial Results Full-year Results Impacted by Lower Demand for COVID-19 Testing Announced Initiation of Clinical Evaluations for Co-Dx PCR Home™ PlatformĬommon Stock Purchase Warrant issued to Coltrin & Associates dated February 6, 2020Īmendment dated Jto Common Stock Purchase Warrant issued to Coltrin & Associates dated October 31, 2019Ĭommon Stock Purchase Warrant issued to Coltrin & Associates dated October 31, 2019Ĭo-Diagnostics, Inc. Letter of Haynie & Company Regarding Change in Certifying Accountant.Ĭo-Diagnostics, Inc. Reports First Quarter 2023 Financial Results Clinical trials for Co-Dx PCR Home™ platform remain on track Solid cash position and grant funding support long-term strategy Change in Control Severance PlanĬo-Diagnostics, Inc. Reports Second Quarter 2023 Financial Results Co-Dx receives grant awards from the Bill & Melinda Gates Foundation NIH RADx® Tech to develop tests on our new Co-Dx PCR Home™ platformĬommercial Lease Agreement, dated June 1, 2023, between Ozone Biotech, LLC and Co-Diagnostics, Inc.Ĭo-Diagnostics, Inc. Reports Third Quarter 2023 Financial Results Receives grant award from the Bill & Melinda Gates Foundation in the amount of $9.0M for the development of tuberculosis test on Co-Dx™ PCR platform.Ĭo-Diagnostics, Inc. Small Cap Value ETFįIDELITY CONCORD STREET TRUST - Fidelity Extended Market Index FundįIRST TRUST EXCHANGE-TRADED FUND - First Trust Dow Jones Select MicroCap Index FundįIDELITY CONCORD STREET TRUST - Fidelity Total Market Index FundįIDELITY CONCORD STREET TRUST - Fidelity Series Total Market Index FundĬo-Diagnostics, Inc. VANGUARD INDEX FUNDS - Vanguard Extended Market Index Fund Investor SharesīRIDGEWAY FUNDS INC - Ultra-Small Company Fund Class NĪMERICAN CENTURY ETF TRUST - Avantis U.S. VANGUARD INDEX FUNDS - Vanguard Total Stock Market Index Fund Investor Shares This data is sourced directly from the SEC via 13F and NPORT filings. This table shows the top 25 institutional owners of the company. Small Cap Value ETF, and FSMAX - Fidelity Extended Market Index Fund. Vanguard Group Inc, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Renaissance Technologies Llc, BlackRock Inc., VEXMX - Vanguard Extended Market Index Fund Investor Shares, Geode Capital Management, Llc, Bridgeway Capital Management Inc, BRUSX - Ultra-Small Company Fund Class N, AVUV - Avantis U.S. These institutions hold a total of 4,776,857 shares. ![]() 68 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |